Physician profile
Jessimar Sanchez
NPI 1376036442
$4,684.21
in general payments reported to CMS, 2019-2025
19 companies · $4,336 in 2025
The $4,336 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $348 · 2025: $4,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328 · Travel and Lodging: $2,277 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.45 |
| Travel and Lodging | $2,276.77 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,276.77 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,115.24 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $478.89 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $160.86 | 2024-2025 | |
| United Therapeutics Corporation | $118.82 | 2024-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $80.07 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Ani Pharmaceuticals, INC. | $78.87 | 2025 | Purified Cortrophin Gel |
| Insmed, INC. | $62.64 | 2024-2025 | Arikayce |
| Amgen INC. | $48.55 | 2025 | Tezspire |
| Zoll Respicardia, INC. | $29.64 | 2025 | Remede System |
| Optinose US, INC. | $25.22 | 2024 | |
| Paratek Pharmaceuticals, INC. | $21.08 | 2025 | Nuzyra, Xhance |
| Pulmonx Corporation | $20.11 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $20.04 | 2025 | Prolastin-C Liquid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $19.61 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $16.89 | 2025 | Dupixent |
| Verona Pharma, INC. | $16.28 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $15.64 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessimar Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.